Tags

Type your tag names separated by a space and hit enter

Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration.
J Ocul Pharmacol Ther 2006; 22(3):194-9JO

Abstract

OBJECTIVE

The aim of this study was to evaluate the duration of the effect of an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) on visual acuity and intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD) with subfoveal choroidal neovascularization.

PARTICIPANTS

The prospective, clinical, interventional, case series study included 69 patients (71 eyes) with exudative AMD who showed an increase in visual acuity by at least 2 Snellen lines after an intravitreal injection of approximately 20 mg TA. Mean follow-up was 11.5 +/- 7.4 months (3.3-35.7 months). The main outcome measure was visual acuity.

RESULTS

Within the first week after the injection, visual acuity and IOP started to increase significantly (P < 0.001) by reaching a plateau-like maximum at 1-6 months after the injection. Visual acuity and IOP returned to baseline values 7-9 months after the injection. Increase of IOP was statistically (P = 0.72) independent of the change in visual acuity.

CONCLUSIONS

In patients with exudative AMD, who have shown an increase of at least 2 Snellen lines in visual acuity, the effect of intravitreal TA (dosage approximately 20 mg) lasts 7-9 months with respect to an increase in visual acuity and IOP.

Authors+Show Affiliations

Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the Ruprecht-Karls-University of Heidelberg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16808681

Citation

Jonas, Jost B., et al. "Duration of the Effect of Intravitreal Triamcinolone Acetonide in Eyes With Exudative Age-related Macular Degeneration." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 22, no. 3, 2006, pp. 194-9.
Jonas JB, Spandau UH, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration. J Ocul Pharmacol Ther. 2006;22(3):194-9.
Jonas, J. B., Spandau, U. H., Kamppeter, B. A., Degenring, R. F., Kreissig, I., Akkoyun, I., & Vossmerbaeumer, U. (2006). Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 22(3), pp. 194-9.
Jonas JB, et al. Duration of the Effect of Intravitreal Triamcinolone Acetonide in Eyes With Exudative Age-related Macular Degeneration. J Ocul Pharmacol Ther. 2006;22(3):194-9. PubMed PMID: 16808681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration. AU - Jonas,Jost B, AU - Spandau,Ulrich H M, AU - Kamppeter,Bernd A, AU - Degenring,Robert F, AU - Kreissig,Ingrid, AU - Akkoyun,Imren, AU - Vossmerbaeumer,Urs, PY - 2006/7/1/pubmed PY - 2006/11/4/medline PY - 2006/7/1/entrez SP - 194 EP - 9 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 22 IS - 3 N2 - OBJECTIVE: The aim of this study was to evaluate the duration of the effect of an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) on visual acuity and intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD) with subfoveal choroidal neovascularization. PARTICIPANTS: The prospective, clinical, interventional, case series study included 69 patients (71 eyes) with exudative AMD who showed an increase in visual acuity by at least 2 Snellen lines after an intravitreal injection of approximately 20 mg TA. Mean follow-up was 11.5 +/- 7.4 months (3.3-35.7 months). The main outcome measure was visual acuity. RESULTS: Within the first week after the injection, visual acuity and IOP started to increase significantly (P < 0.001) by reaching a plateau-like maximum at 1-6 months after the injection. Visual acuity and IOP returned to baseline values 7-9 months after the injection. Increase of IOP was statistically (P = 0.72) independent of the change in visual acuity. CONCLUSIONS: In patients with exudative AMD, who have shown an increase of at least 2 Snellen lines in visual acuity, the effect of intravitreal TA (dosage approximately 20 mg) lasts 7-9 months with respect to an increase in visual acuity and IOP. SN - 1080-7683 UR - https://www.unboundmedicine.com/medline/citation/16808681/Duration_of_the_effect_of_intravitreal_triamcinolone_acetonide_in_eyes_with_exudative_age_related_macular_degeneration_ L2 - https://www.liebertpub.com/doi/full/10.1089/jop.2006.22.194?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -